Learn about Cannabinol, CBN, Rare Cannabinoids, EB, Glaucoma

Skip to content

Facebook Twitter Linkedin

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Latest Events

InMed’s CEO, Eric A. Adams, at J.P. Morgan Healthcare Conference

Date: Jan 13-16, 2025

Fierce Biotech Webinar: Alzheimer’s Outlook – Neuroinflammation, the Next Step

Date: November 12, 2024

Time: 2:00pm ET

Add to Calendar

H.C. Wainwright 26th Annual Global Investment Conference

Date: September 9-11, 2024

Add to Calendar

Alzheimer’s Association International Conference®

Date: July 28 – August 1, 2024

Add to Calendar

Emerging Growth Conference

Date: June 13, 2024

Time: 1:45pm EDT

Add to Calendar

Benzinga Healthcare + Biotech Breakthroughs

Date: June 20, 2024

Time: 11:00am ET

Add to Calendar

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.

#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

INM-901 for Alzheimer’s Disease
INM-089 for Age-related Macular Degeneration
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Novel Analogs

MANUFACTURING

BayMedica – Rare Cannabinoid Ingredients
Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM Materials
Filings
Presentations
Media & Videos
Investor Contact

CORPORATE

Management
Board of Directors
Scientific Advisors
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent*

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.

CAPTCHA